Taiwan's Adimmune Set For Quick Production Of Rapiacta Against H7N9
This article was originally published in PharmAsia News
The chairman of Taiwan-based Adimmune said that as soon as the firm receives a sample of the H7N9 avian influenza virus the subject of an outbreak in China, it would begin emergency production of its Rapiacta (peramivir).
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.